

## VLCCR Clinical Quality Indicators

No.	Indicator
<b>Timeliness Indicators</b>	
1	Proportion of patients where referral to diagnosis date $\leq$ 28 days.
2	Proportion of patient where time from diagnosis to first treatment (any intent) $\leq$ 14 days.
3	Proportion of patients with NSCLC where time from diagnosis to surgical resection $\leq$ 14 days.
4	Proportion of patients where referral to first treatment (any intent) is $\leq$ 42 days.
<b>Documentation in medical records indicators</b>	
5	Proportion of patients with documented supportive care screening.
6	Proportion of patients with documented ECOG status.
7	Proportion of patients with NSCLC who have clinical staging (cTNM) documented.
8	Number of patients with documented MDM presentation.
9	Proportion of patients with NSCLC undergoing surgical resection with documented PET scan.
<b>Stage concordance and tissue diagnosis indicators</b>	
10	Proportion of patients with NSCLC who have had a surgical resection and clinical stage agrees with pathological stage.
11	Proportion of patients with confirmed tissue diagnosis (malignant cytology, histology).
<b>Treatment indicators</b>	
12	Proportion of patients with NSCLC (clinical stage I, II) who had a surgical resection.
13	Proportion of patients with NSCLC (clinical stage I,II) who have had a resection with $\geq$ 5 lymph nodes identified in the pathology report.
14	Proportion of patients with NSCLC who have had a resection and date of death within 30 days of surgery.
15	Proportion of patients with NSCLC who have had a resection and date of death within 90 days of surgery.
16	Proportion of patients receiving anti-cancer treatment-any intent (resection, radiation therapy, or systemic anti-cancer therapy (SACT)).
17	Proportion of patients with NSCLC (clinical stage IIIB, IIIC or IV) who have ECOG (0-1) who have received SACT.
18	Proportion of patients with NSCLC (path stage II, III) receiving adjuvant platinum based chemotherapy following resection.
19	Proportion of patients in registry where the time from the start date of SACT to death date is $\leq$ 30 days.
<b>Palliative care indicator</b>	
20	Proportion of patients with NSCLC (stage IV) referred to palliative care within $\leq$ 8 weeks of diagnosis.
<b>Molecular indicators</b>	
21	Proportion of patients with NSCLC non-squamous (stage IV) who have been tested for EGFR.

<b>Molecular Indicators cont.</b>	
22	Proportion of patients with NSCLC non-squamous (stage IV) who have been tested for ALK.
23	Proportion of patients with NSCLC non-squamous (stage IV) who have been tested for ROS1.
24	Proportion of patients with NSCLC non-squamous (stage IV) who have been tested for PDL1.

## VLCR Quality Indicator Definitions

<b>No.</b>	<b>Numerator</b>	<b>Denominator</b>
<b>Timeliness Indicators</b>		
1	Number of patients where time from referral to date to diagnosis is $\leq 28$ days.	Number of patients in registry with referral and diagnosis dates available.
2	Number of patients where time from diagnosis to first treatment date is $\leq 14$ days.	Number of patients in registry receiving anti-cancer treatment with diagnosis and treatment dates available.
3	Number of patients with NSCLC where time from diagnosis to surgical resection is $\leq 14$ days.	Total number of NSCLC patients undergoing surgical resection with diagnosis and resection dates available.
4	Number of patients where time from referral date to first treatment date is $\leq 42$ days.	Total number of patients undergoing any intent anti-cancer treatment with referral and first treatment dates available.
<b>Documentation in medical records indicators</b>		
5	Number of patients with documented screening for supportive care.	Number of patients in the registry.
6	Number of patients with documented ECOG status.	Number of patients in registry.
7	Number of patients with NSCLC and documented clinical (cTNM) staging.	Total number of NSCLC patients.
8	Number of patients with documented MDM presentation.	Number of patients in registry.
9	Number of patients with documented PET scan.	Number of NSCLC patients undergoing surgical resection.
<b>Stage concordance and tissue diagnosis indicators</b>		
10	Number of NSCLC patients undergoing surgical resection where cTN agrees with pTN.	Total number of patients with NSCLC who have had a surgical resection with cTN and pTN available.
11	Number of patients with confirmed tissue diagnosis.	Number of patients in the registry.
<b>Treatment indicators</b>		
12	Number of patients who have had a surgical resection.	Total number of NSCLC patients with clinical stage I-II.

<b>Treatment indicators cont.</b>		
13	Number of patients with $\geq 5$ lymph nodes identified in pathology report.	Number of NSCLC patients (clinical stage I-II) who have undergone a surgical resection.
14	Number of patients who have had a surgical resection and died within $\leq 30$ days of surgery.	Number of NSCLC patients who have undergone a surgical resection.
15	Number of NSCLC patients with NSCLC who have had a surgical resection and died $\leq 90$ days of surgery.	Number of NSCLC patients who have undergone a surgical resection.
16	Number of patients receiving anti-cancer treatment (resection, radiotherapy, chemotherapy, immunotherapy, or targeted therapy).	Number of patients in the registry.
17	Number of patients who have received SACT.	Number of patients with NSCLC stage IIIB, IIIC or IV who have ECOG (0-1).
18	Number of patients who have had an adjuvant platinum-based chemotherapy.	Number of NSCLC patients (pathological stage II-III) who have undergone a surgical resection.
19	Number of patients with lung cancer where time from the start date of SACT to death date is $\leq 30$ days.	Number of patients receiving SACT.
<b>Palliative care indicator</b>		
20	Number of patients who have had a palliative care referral $\leq 8$ weeks of diagnosis.	Number of patients with lung cancer type NSCLC (stage IV) and palliative care referral date available.
<b>Molecular indicators</b>		
21	Number of patients who have had EGFR testing.	Number of patients with NSCLC non-squamous (stage IV).
22	Number of patients who have had ALK testing.	Number of patients with NSCLC non-squamous (stage IV).
23	Number of patients who have had ROS1 testing.	Number of patients with NSCLC non-squamous (stage IV).
24	Number of patients who have had PDL1 testing.	Number of patients with NSCLC stage IV.